PDCD1 and neoplasm: In addition, an objective response rate of 29% was observed in the group having a higher tumor mutational burden (TMB) in advanced solid tumor patients when receiving the PD-1 blockade pembrolizumab as monotherapy (Marabelle et al., 2020).